Anacor Pharmaceuticals to Present Pivotal Phase 3 Data of Tavaborole for the Topical Treatment of Toenail Onychomycosis

  Anacor Pharmaceuticals to Present Pivotal Phase 3 Data of Tavaborole for the
  Topical Treatment of Toenail Onychomycosis

Abstract Accepted for Oral Presentation at the 2013 American Podiatric Medical
                    Association Annual Scientific Meeting

Business Wire

PALO ALTO, Calif. -- July 18, 2013

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that its abstract
“Pivotal Phase 3 Safety and Efficacy Results of Tavaborole (Formerly AN2690),
a Novel Boron-Based Molecule for the Topical Treatment of Toenail
Onychomycosis” was accepted for oral presentation at the 2013 APMA Annual
Scientific Meeting (The National) to be held in Las Vegas, Nevada. Max
Weisfeld, DPM, will present the data from tavaborole’s Phase 3 studies on
Monday, July 22, 2013 during the Evidence-Based Medicine and Oral Abstracts
session.

As announced earlier this year, tavaborole achieved statistically significant
and clinically meaningful results on all primary and secondary endpoints in
two Phase 3 pivotal studies without concomitant debridement. Anacor is seeking
approval for tavaborole from the Food and Drug Administration (FDA) and will
file a New Drug Application imminently. Currently, there is only one
FDA-approved topical treatment for onychomycosis, a fungal infection of the
nail and nail bed, which affects approximately 35 million people in the United
States.

“I’m impressed with tavaborole’s safety and efficacy data. There is no
FDA-approved topical treatment for onychomycosis with tavaborole’s range of
efficacy and ability to penetrate the nail to reach the site of the
infection,” said Dr. Weisfeld. “Tavaborole’s Phase 3 results demonstrate its
ability to clear the nail and eliminate the infection which is important to
both patients and the physicians who treat them. In addition, tavaborole is
easy to apply and dries quickly which makes it convenient for patients to
use.”

“We are pleased to present these positive data at the APMA’s Annual Scientific
Meeting, the leading annual meeting of podiatrists. As we seek FDA approval
for tavaborole, we look forward to developing relationships with podiatrists
to potentially offer them a new treatment option for the large number of
patients who seek treatment for onychomycosis,” said David Perry, Chief
Executive Officer of Anacor Pharmaceuticals.

About the Studies

Anacor conducted two separate Phase 3 studies of tavaborole on patients with
distal subungual onychomycosis affecting 20 to 60 percent of the target great
toenail. Approximately 600 patients aged 18 years and older with no upper age
limit (the oldest subject was 88 years old) were enrolled in each study and
randomized two-to-one to receive either tavaborole or the vehicle control.
Patients were instructed to apply tavaborole solution or the vehicle to the
toenail once daily for 48 weeks.

A copy of the presentation will be available on Anacor’s website following the
oral session.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and
commercializing novel small-molecule therapeutics derived from its boron
chemistry platform. Anacor has discovered eight compounds that are currently
in development. Its two lead product candidates are topically administered
dermatologic compounds — tavaborole, a topical antifungal for the treatment of
onychomycosis, and AN2728, a topical anti-inflammatory PDE-4 inhibitor for the
treatment of atopic dermatitis and psoriasis. In addition to its two lead
programs, Anacor has discovered three other wholly-owned clinical product
candidates — AN2718 and AN2898, which are backup compounds to tavaborole and
AN2728, respectively, and AN3365 an antibiotic for the treatment of infections
caused by Gram-negative bacteria. We have discovered three other compounds
that we have out-licensed for further development — two compounds for the
treatment of animal health indications that are licensed to Eli Lilly and
Company and AN5568, also referred to as SCYX-7158, for human African
trypanosomiasis (HAT, or sleeping sickness), which is licensed to Drugs for
Neglected Diseases initiative, or DNDi. We also have a pipeline of other
internally discovered topical and systemic boron-based compounds in
development. For more information, visit http://www.anacor.com.

Forward-Looking Statements

This press release may contain forward-looking statements that relate to
future events including the timing for filing of a new drug application, or
NDA, related to tavaborole and the potential FDAapproval of tavaborole. These
forward looking statements involve known and unknown risks, uncertainties and
other factors that could cause actual levels of activity, performance or
achievement to differ materially from those expressed or implied by these
forward-looking statements, including risks related to regulatory approval of
new drug candidates. Reference should be made to Anacor's Annual Report on
Form 10-K for the year endedDecember 31, 2012, filed with theSecurities and
Exchange Commissionunder the heading "Risk Factors" and Anacor's subsequent
Quarterly Reports on Form 10-Q for a more detailed description of such
factors. These statements reflect the views of Anacor as of the date of this
press release with respect to future events and, except as required by law, it
undertakes no obligation to update or revise publicly any forward-looking
statements, whether as a result of new information, future events or otherwise
after the date of this press release.

Contact:

Anacor Pharmaceuticals
DeDe Sheel, 650-543-7575
Director, Investor Relations and Corporate Communications
dsheel@anacor.com